Biopharmaceuticals
Dianthus Therapeutics is a biopharmaceutical company developing potentially best-in-class therapies for patients with severe autoimmune diseases. Their lead candidate, claseprubart (DNTH103), is an engineered antibody with extended half-life and high selectivity for active C1s complement protein, designed for convenient self-administered subcutaneous injections. Their second clinical candidate, DNTH212, is a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation for improved clinical outcomes. The company is focused on advancing monoclonal antibodies and biotherapeutics through scalable manufacturing processes and global development of their expanding pipeline.
Industry
Biopharmaceuticals
Remote Policy
Office-first with remote options
Beta · Sourced from candidate reports
Be the first to share your experience with Dianthus Therapeutics.
Your reply helps other candidates know what to expect.
